The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
Abstract
This paper looks at a new approach to the design and analysis of Phase 1 clinical trials in cancer. The basic idea and motivation behind the approach stem from an attempt to reconcile the needs of dose-finding experimentation with the ethical demands of established medical practice. It is argued that for these trials the particular shape of the dose toxicity curve is of little interest. Attention focuses rather on identifying a dose with a given targeted toxicity level and on concentrating experimentation at that which all current available evidence indicates to be the best estimate of this level. Such an approach not only makes an explicit attempt to meet ethical requirements but also enables the use of models whose only requirements are that locally (i.e., around the dose corresponding to the targeted toxicity level) they reasonably well approximate the true probability of toxic response. Although a large number of models could be contemplated, we look at a particularly simple one. Extensive simulations show the model to have real promise.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and Analysis of Phase I Clinical Trials
Storer, B. E. (1989) · Biometrics · doi:10.2307/2531693 · Cited by 930
Bayesian Reliability Analysis.
Hill, B. M., Martz, H. F., & Waller, R. A. (1985) · Journal of the American Statistical Association · doi:10.2307/2288105 · Cited by 703
Potential roles for preclinical pharmacology in phase I clinical trials.
Collins, J. M., Zaharko, D. S., Dedrick, R. L., et al. (1986) · PubMed · Cited by 213
Bayesian Methods: General Background
Jaynes, E. T. (1986) · Maximum Entropy and Bayesian Methods in Applied Statistics · doi:10.1017/cbo9780511569678.003 · Cited by 185
Cited by
Bayesian Approaches to Clinical Trials and Health‐Care Evaluation
Spiegelhalter, D. J., Abrams, K. R., & Myles, J. P. (2003) · Wiley eBooks · doi:10.1002/0470092602 · Cited by 1,673
Dose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639
Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
Cheung, Y. K., & Chappell, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.01177.x · Cited by 545
Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs
Thall, P. F., & Cook, J. D. (2004) · Biometrics · doi:10.1111/j.0006-341x.2004.00218.x · Cited by 522
Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., & Armand, J.-P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.116 · Cited by 499
Adaptive design methods in clinical trials–a review
Chow, S.-C., & Chang, M. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-11 · Cited by 482
“For adaptive dose finding design, the method of continual re-assessment method (CRM) in conjunction with Bayesian approach is usually considered [34-36].”
Some practical improvements in the continual reassessment method for phase I studies
Goodman, S. N., Zahurak, M. L., & Piantadosi, S. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141102 · Cited by 472
Critical aspects of the Bayesian approach to phase I cancer trials
Neuenschwander, B., Branson, M., & Gsponer, T. (2008) · Statistics in Medicine · doi:10.1002/sim.3230 · Cited by 439
Papandreou, C. N., Daliani, D. D., Nix, D., Yang, H., Madden, T., Wang, X., Pien, C. S., Millikan, R. E., Tu, S.-M., Pagliaro, L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.106 · Cited by 434
de Lima, M., Giralt, S., Thall, P. F., de Padua Silva, L., Jones, R. B., Komanduri, K., Braun, T. M., Nguyen, H. Q., Champlin, R., & Garcia‐Manero, G. (2010) · Cancer · doi:10.1002/cncr.25500 · Cited by 427
Continual Reassessment Method: A Likelihood Approach
O'Quigley, J., & Shen, L. Z. (1996) · Biometrics · doi:10.2307/2532905 · Cited by 382
Self-citationBayesian methods in health technology assessment: a review.
Spiegelhalter, Myles, Jones, & Abrams (2000) · Health Technology Assessment · doi:10.3310/hta4380 · Cited by 358
Bayesian optimal interval designs for phase I clinical trials
Liu, S., & Yuan, Y. (2015) · Journal of the Royal Statistical Society: Series C (Applied Statistics) · doi:10.1111/rssc.12089 · Cited by 350
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
Seymour, J. F., Ma, S., Brander, D. M., Choi, M. Y., Barrientos, J., Davids, M. S., Anderson, M. A., Beaven, A. W., Rosen, S. T., Tam, C. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30012-8 · Cited by 333
Ruan, J., Martin, P., Furman, R. R., Lee, S. M., Cheung, K., Vose, J. M., LaCasce, A., Morrison, J., Elstrom, R., Ely, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1142 · Cited by 319
A comparison of two phase I trial designs
Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C., & Simon, R. M. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131802 · Cited by 303
Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design
Skolnik, J. M., Barrett, J. S., Jayaraman, B., Patel, D., & Adamson, P. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7712 · Cited by 282
Envisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & de Bono, J. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2870 · Cited by 281
Thall, P. F., & Russell, K. E. (1998) · Biometrics · doi:10.2307/2534012 · Cited by 278
A modified toxicity probability interval method for dose-finding trials
Ji, Y., Liu, P., Li, Y., & Nebiyou Bekele, B. (2010) · Clinical Trials · doi:10.1177/1740774510382799 · Cited by 273
Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
Bryant, J., & Day, R. (1995) · Biometrics · doi:10.2307/2533268 · Cited by 260
Geletneky, K., Hajda, J., Angelova, A. L., Leuchs, B., Capper, D., Bartsch, A. J., Neumann, J.-O., Schöning, T., Hüsing, J., Beelte, B., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.016 · Cited by 260
Adaptive trial designs: a review of barriers and opportunities
Kairalla, J. A., Coffey, C. S., Thomann, M. A., & Muller, K. E. (2012) · Trials · doi:10.1186/1745-6215-13-145 · Cited by 249
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials
(2016) · doi:10.1158/1078-0432.ccr-16-0592 · Cited by 235
Translation of Innovative Designs Into Phase I Trials
Rogatko, A., Schoeneck, D., Jonas, W., Tighiouart, M., Khuri, F. R., & Porter, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1012 · Cited by 217
Adaptive Designs for Randomized Trials in Public Health
Brown, C. H., Ten Have, T. R., Jo, B., Dagne, G., Wyman, P. A., Muthén, B., & Gibbons, R. D. (2009) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.031308.100223 · Cited by 184
Novel Methods and Technologies for 21st-Century Clinical Trials: A Review
Dorsey, E. R., Venuto, C., Venkataraman, V., Harris, D. A., & Kieburtz, K. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4524 · Cited by 118
Papadopoulos, K. P., Borazanci, E., Shaw, A. T., Katayama, R., Shimizu, Y., Zhu, V. W., Sun, T. Y., Wakelee, H. A., Madison, R., Schrock, A. B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1630 · Cited by 113
Operating characteristics of the standard phase I clinical trial design
Reiner, E., Paoletti, X., & O'Quigley, J. (1999) · Computational Statistics & Data Analysis · doi:10.1016/s0167-9473(98)00095-4 · Cited by 104
Self-citationCraddock, C., Slade, D., De Santo, C., Wheat, R., Ferguson, P., Hodgkinson, A., Brock, K., Cavenagh, J., Ingram, W., Dennis, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00889 · Cited by 73
Rethinking clinical trials for medical AI with dynamic deployments of adaptive systems
Rosenthal, J. T., Beecy, A., & Sabuncu, M. R. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01674-3 · Cited by 59
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer
Dumez, H., Gall, H., Capdeville, R., Dutreix, C., van Oosterom, A. T., & Giaccone, G. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328010ef5b · Cited by 52
Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies
Tosi, D., Laghzali, Y., Vinches, M., Alexandre, M., Homicsko, K., Fasolo, A., Del Conte, G., Durigova, A., Hayaoui, N., Gourgou, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1082 · Cited by 33
Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
Coffman, L. G., Orellana, T. J., Liu, T., Frisbie, L. G., Normolle, D., Griffith, K., Uppal, S., McLean, K., Berger, J., Boisen, M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160573 · Cited by 17
Metadata
- Authors
- O'Quigley, J., Pepe, M., & Fisher, L.
- Venue
- Biometrics
- Publisher
- JSTOR
- Published
- 1990-03
- Volume
- 46
- Issue
- 1
- Pages
- 33
- ISSN
- 0006-341X (ISSN-L)
- OpenAlex
- W2076108528
- Cited by
- 1,577
- References
- 4
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.